SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Dynogen Pharma gets $50M round (TheDeal.com)
News | 04. 19. 2004
Dynogen Pharmaceuticals
Boston-based Dynogen Pharmaceuticals Inc. said Monday, April 19, it had secured a $50 million B round of financing that it will use to further develop its neuroscientific approach to treating genitourinary and gastrointestinal disorders.
